Roche Discussing Phase III Study with FDA for Personalized Asthma Drug Lebrikizumab
August 10, 2011
Roche Discussing Phase III Study with FDA for Personalized Asthma Drug Lebrikizumab
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Yale Researcher Suggests More Focus on EGFR Isoforms Needed in Development of Antibody-Based Drugs
May 20, 2011 / ProteoMonitor - PGx Drugs Xalkori, Zelboraf Show Strong Growth in First Quarter of 2013
May 1, 2013 / Pharmacogenomics Reporter - Qiagen's Experience Developing KRAS CDx for Erbitux Yields Lessons for Rx/Dx Development
November 28, 2012 / Pharmacogenomics Reporter - Merck Serono Survey Finds Limited Test Access, High Costs a Barrier to Personalized Rx Adoption in UK
May 2, 2012 / Pharmacogenomics Reporter - ODAC Meeting on Accelerated Approval for Oncologics Raises Questions about Strategies for PGx Drugs
February 16, 2011 / Pharmacogenomics Reporter